Shanghai Yingli Pharmaceutical Co., Ltd.

Two Chinese biopharma companies have recently aired their intentions to take stakes in or even acquire some of their peers in a bid to expand their pipelines, despite the ongoing general downturn in t

China’s top drug regulator is planning to impose more stringent rules on how conditional approval, the equivalent of the US Food and Drug Administration’s accelerated approval scheme, will be granted

Shanghai’s biopharma sector is experiencing a resounding recovery after being struck by spikes of COVID-19 cases in the first half of this year. Original innovation incubated by a consortium establish

Scrip regularly reviews technology transfer activity across the biopharmaceutical sector. This edition of Tech Transfer Roundup focuses on oncology deals; the next edition will look at non-oncology de